Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients
Autore:
Ohe, Y; Niho, S; Kakinuma, R; Kubota, K; Matsumoto, T; Ohmatsu, H; Goto, K; Kunitoh, H; Saijo, N; Nishiwaki, Y;
Indirizzi:
Natl Canc Ctr Hosp, Dept Internal Med, Chuo Ku, Tokyo 1040045, Japan Natl Canc Ctr Hosp Tokyo Japan 1040045 ed, Chuo Ku, Tokyo 1040045, Japan
Titolo Testata:
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 3, volume: 31, anno: 2001,
pagine: 100 - 106
SICI:
0368-2811(200103)31:3<100:PISOCA>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRIAL; FEASIBILITY; TAXOTERE; TOXICITY;
Keywords:
asthenia; combination phase I study; docetaxel; elderly patients; non-small cell lung cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Ohe, Y Natl Canc Ctr Hosp, Dept Internal Med, Chuo Ku, 1-1 Tsukiji 5 chome, Tokyo1040045, Japan Natl Canc Ctr Hosp 1-1 Tsukiji 5 chome Tokyo Japan 1040045 , Japan
Citazione:
Y. Ohe et al., "Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients", JPN J CLIN, 31(3), 2001, pp. 100-106

Abstract

Background: To determine the maximum tolerated dose and recommended dose of cisplatin and docetaxel administered by three consecutive weekly infusions in both non-elderly (less than or equal to 74 years) and elderly (greaterthan or equal to 75 years) patients, we conducted two independent phase I studies for non-elderly and elderly patients with non-small cell lung cancer. Methods: Between April 1998 and September 1999, 26 non-elderly (median, 54years; range, 44-73 years) and 12 elderly (median, 76 years; range, 75-80 years) patients with non-small cell lung cancer were entered in these studies. The eligibility criteria of both cohorts were identical except for age. Chemotherapy consisted of cisplatin 25 mg/m(2) and an escalated dose of docetaxel on days 1, 8 and 15 every 4 weeks. The initial dose of docetaxel was 20 mg/m(2) and it was increased by 5 mg/m(2) at each dose level. Results: In the non-elderly and elderly cohorts, up to 45 or 25 mg/m(2) ofdocetaxel, respectively, were administered. Dose-limiting toxicities were neutropenia, liver damage, pneumonia and omission of treatment on day 15 byleukopenia and refusal in the non-elderly cohort; pneumonia and omission of treatment on day 15 by refusal due to fatigue/asthenia or fever in the elderly cohort. We considered the recommended doses for phase II studies werecisplatin 25 mg/m(2) and docetaxel 35 mg/m(2) on days 1, 8 and 15 for non-elderly patients and cisplatin 25 mg/m(2) and docetaxel 20 mg/m(2) on days 1, 8 and 15 for elderly patients. Seven of 26 (27%) and seven of 12 (58%) patients achieved a partial response, median survival times were 8.7 and 7.2months and 1 year survival rates were 27 and 27% in the non-elderly and elderly cohorts, respectively. Conclusions: Further evaluation of this combination chemotherapy is warranted for both non-elderly and elderly patients with non-small cell lung cancer but the dose of docetaxel should be lower for elderly than non-elderly patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 22:39:25